In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Neuren Pharmaceuticals ... Uncover insightful assessments of a stock's market performance and potential with ...
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...
Jefferies analyst David Stanton maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report) today and set a price target of A$27.40. The company’s shares closed last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback